Atrys Health Sa · BME:ATRY
Atrys Health Sa — 9M 2024 Earnings Presentation
12 slides from Atrys Health Sa's earnings presentation, Nov 15, 2024
Slide 1: 9Months Results Presentation
November 15, 2024 9Months Results Presentation
Slide 2: Warning / Disclaimer and Cautionary Statements
Warning / Disclaimer and Cautionary Statements This document and the earnings conference call (including The forward-looking statements or forecasts contained in this Except to the extent required by applicable law, ATRYS the question and answer session) may contain forward- document may be identifi
Slide 3: Atrys, 360º Health Services
Atrys, 360º Health Services We are a global healthcare provider offering innovative and personalized solutions for each patient. We performed more than 7.6 million medical procedures. % OF SALES BUSINESS AREAS 2016 2024 ✓• Monitoring 1M people. 39% ✓• 210 care centers ✓• 7M Telediagnostics ✓• Teledi
Slide 4: Highlight 9M 2024
Highlight 9M 2024 Main magnitudes. Turnover Adjusted EBITDA MAR FC Operational MAR +5,8% +31,7% +60,8% 147,1 155,6 23,7 31,2 18,3 11,4 66,95% 65,96% 9m 2023 9m 2024 9m 2023 9m 2024 9m 2023 9m 2024 Revenue growth of +5.8% and +7.2% at constant exchange rates compared to Adjusted EBITDA increased by +
Slide 5: Key Figures 9M 2024
Key Figures 9M 2024 The good performance of the main aggregates continued in 3Q 2024, with robust EBITDA growth supported by the operating leverage of the business thanks to the growth in activity and the execution of efficiencies. Revenue growth reached 155.6M€ in the first 9 months of fiscal year
Slide 6: Key Figures 9M 2024
Key Figures 9M 2024 Revenue performance by segment and geographic area Diagnostics: Growth of 5.0% (+9.5% at constant exchange rates). In the Diagnostics segment, the good performance of the Laboratory area stands out, +30.9%, due to the positive evolution of the ramp up of the Madrid Laboratory. On
Slide 7: Key figures 9M 2024
Key figures 9M 2024 Last Twelve Month (LTM) Revenue Performance 9,4% At constant exchange rate 8,3% 194,3M€ 201,6M€ 205,0M 207,3M 210,5M€ € € Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 (MAR ) See definitions of alternative performance measures in Annex I. Unaudited figures. LatAm = Brazil, Chile,
Slide 8: Key Figures 9M 2024
Key Figures 9M 2024 Evolution of Gross Margin and Adjusted EBITDA over Net Revenues (%) by segment Diagnostics: Gross Margin improved by +40 b.p. as a result of the optimizations introduced in the Online Diagnostics platforms, which improved its gross margin on revenues from 44.8% to 45.8%, and Labo
Slide 9: Highlight 9M 2024
Highlight 9M 2024 Good performance of the main business figures in the first 9 months of 2024: +7.2% growth in revenues, +31.7% increase in Adjusted EBITDA with an improvement in the Adjusted EBITDA margin over revenues from 16.09% to 20.02% and an increase in Operating Cash Flow of +60.8% due to EB
Slide 10: Thank you!
fo ‘L <> atrys Thankyou!
Slide 11: Annex II
Annex II As well as the amount of incentive plans for the Group's Alternative Average Yield Definitions (MAR) management team recognized in an expense account that do not involve a cash outflow. GROSS MARGIN (MAR) Gross Margin(MAR) corresponds to net sales less supplies. In addition, the synergies d
Slide 12: Annex II
Annex II Alternative Average Yield Definitions (MAR) OPERATING CASH FLOW (MAR) Operating cash flow(MAR) means EBITDA(MAR) for the period minus CAPEX(MAR) and CAPEX R&D . (MAR) ADJUSTED OPERATING CASH Adjusted operating cash flow(MAR) means adjusted EBITDA(MAR) for the period less CAPEX (MAR) and CAP